NF-κB Mediates IL-1β- and IL-17A-Induced MUC5B Expression in Airway Epithelial Cells

A major pathological feature of chronic airway diseases is the elevated expression of gel-forming mucins. NF-kappa B activation in airway epithelial cells has been shown to play a proinflammatory role in chronic airway diseases; however, the specific role of NF-kappa B in mucin gene expression has not been characterized. In this study, we show that the proinflammatory cytokines, IL-1 beta and IL-17A, both of which use the NF-kappa B pathway, are potent inducers of MUC5B mRNA expression in both well differentiated primary normal human bronchial epithelial cells and the human bronchial epithelial cell line, HBE1. MUC5B induction by these cytokines was both time-and dose-dependent, and was attenuated by the small molecule inhibitor, NF-kappa B inhibitor III, as well as p65 small interfering RNA, suggesting that the regulation of MUC5B expression by these cytokines is via an NF-kappa B-based transcriptional mechanism. Deletion analysis of the MUC5B promoter demonstrated that IL-1 beta- and IL-17A-induced promoter activity resides within the -4.17-kb to -2.56-kb region relative to the transcriptional start site. This region contains three putative kappa B-binding sites (NF-kappa B-1, -3,786/-3,774; NF-kappa B-2, -3,173/-3,161; and NF-kappa B-3, -2,921/-2,909). Chromatin immunoprecipitation analysis confirmed enhanced binding of the p50 NF-kappa B subunit to the NF-kappa B-3 site after cytokine stimulation. We conclude that an NF-kappa B-based transcriptional mechanism is involved in MUC5B regulation by IL-1 beta and IL-17A in airway epithelium. This is the first demonstration of the participation of NF-kappa B and its specific binding site in cytokine-mediated airway MUC5B expression.